<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245894</url>
  </required_header>
  <id_info>
    <org_study_id>VF-20060</org_study_id>
    <nct_id>NCT01245894</nct_id>
  </id_info>
  <brief_title>Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment</brief_title>
  <official_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on the Coronary Microcirculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to measure the effect of low- and high-dose lipid-lowering&#xD;
      treatment with rosuvastatin on the coronary physiology parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint was the change from baseline in Index of microcirculatory resistance(IMR).</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints were the changes from baseline in Fractional Flow Reserve (FFR) and lipid values.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Myocardial Infarction [C14.907.585.500]</condition>
  <arm_group>
    <arm_group_label>Low-dose Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg Rosuvastatin/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 40mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Rosuvastatin</intervention_name>
    <description>Rosuvastatin 5mg/day for one year</description>
    <arm_group_label>Low-dose Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose Rosuvastatin</intervention_name>
    <description>Rosuvastatin 40mg/day for one year</description>
    <arm_group_label>High-dose Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ST-segment elevation myocardial infarction&#xD;
&#xD;
          2. no prior treatment with statins and&#xD;
&#xD;
          3. a non significant lesion in one of the two non-culprit coronary arteries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. age below 18 or above 81 years,&#xD;
&#xD;
          2. unconscious patients,&#xD;
&#xD;
          3. serum creatinine &gt; 176Î¼mol/L,&#xD;
&#xD;
          4. hypothyroidism ((TSH &gt; 1.5 x ULN (upper limit of normal)),&#xD;
&#xD;
          5. current liver disease (ALAT &gt; 2 x ULN),&#xD;
&#xD;
          6. unexplained creatine kinase &gt; 3 x ULN,&#xD;
&#xD;
          7. alcohol or drug abuse within the last five years,&#xD;
&#xD;
          8. prior myopathy or serious hypersensitivity reaction caused by statins,&#xD;
&#xD;
          9. women with childbearing potential who were not using chemical or mechanical&#xD;
             contraception,&#xD;
&#xD;
         10. pregnant or breastfeeding women,&#xD;
&#xD;
         11. history of malignancy unless a disease-free period of more than five years was&#xD;
             present,&#xD;
&#xD;
         12. patients with abnormal lung function test (LFT),&#xD;
&#xD;
         13. participation in another investigational drug study less than four weeks before&#xD;
             enrolment in the present study,&#xD;
&#xD;
         14. treatment with cyclosporine or fibrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Egede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fuenen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>MD Rasmus Egede</name_title>
    <organization>Department of Cardiology, Odense University Hospital</organization>
  </responsible_party>
  <keyword>Index of microcirculatory resistance</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

